Five patients with tardive dyskinesia (average age, 64 years) were treated with a central dopamine blocking agent, metoclopramide hydrochloride. The duration of symptoms ranged from four to 30 months. A pretreatment disability score was graded (0 to 4) for buccolingual, extremity, and truncal movements and for duration of tongue protrusion. A 59% improvement was achieved in total disability scores. Tongue protrusion demonstrated the most noticeable improvement. The average daily dosage ranged from a minimum of 20 mg to a maximum of 80 mg given in divided doses. Duration of follow-up ranged from three to eight months. Preliminary data suggest that metoclopramide may be effective in the treatment of tardive dyskinesia.
Karp JM, Perkel MS, Hersh T, McKinney AS. Metoclopramide Treatment of Tardive Dyskinesia. JAMA. 1981;246(17):1934–1935. doi:10.1001/jama.1981.03320170046029
Customize your JAMA Network experience by selecting one or more topics from the list below.